ImmuCell Stock

ImmuCell EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of ImmuCell (ICCC) as of Aug 8, 2026 is 36.20. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -36.06 — a change of -200.38% (higher).

EV/EBIT

36.20

YoY

-200.38%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of ImmuCell is 2026 36.20 . EV/EBIT (Enterprise Value to EBIT) of ImmuCell was 2025 -36.06 . It decreases by -200.38% higher compared to the previous year.

The ImmuCell EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-29.19 base
Jan 1, 2020
-31.11 base
Jan 1, 2021
238.04 base
Jan 1, 2022
-20.56 base
Jan 1, 2023
-7.18 base
Jan 1, 2024
-27.79 base
Jan 1, 2025
33.73 base
Jan 1, 2026 (e)
-68.01 base
YEARPRICE-TO-EBIT
2026 est -68.01
2025 33.73
2024 -27.79
2023 -7.18
2022 -20.56
2021 238.04
2020 -31.11
2019 -29.19
2018 -26.81
2017 -184.66
2016 32.40
2015 13.62
2014 -71.28
2013 -661.05
2012 49.29
2011 -22.17
2010 -13.79
2009 -20.91
2008 -4.15
2007 11.77
2006 22.37
Access this data via the Eulerpool API
Get Free API Key

ImmuCell Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides ImmuCell's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates ImmuCell's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots ImmuCell's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if ImmuCell grows earnings faster than its peers.

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

EV/EBIT (Enterprise Value to EBIT) of ImmuCell is 36.20 in 2026.

EV/EBIT (Enterprise Value to EBIT) of ImmuCell changed from -36.06 to 36.20, representing a -200.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) ImmuCell since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s ImmuCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — ImmuCell

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — ImmuCell